Cargando…
Developments in administration of growth hormone treatment: focus on Norditropin(®) Flexpro(®)
Recombinant human growth hormone is used for the treatment of growth failure in children and metabolic dysfunction in adults with growth hormone deficiency. However, conventional growth hormone therapy requires daily subcutaneous injections that may affect treatment adherence, and subsequently effic...
Autores principales: | Yuen, Kevin CJ, Amin, Rakesh |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3063658/ https://www.ncbi.nlm.nih.gov/pubmed/21448295 http://dx.doi.org/10.2147/PPA.S10985 |
Ejemplares similares
-
Population Pharmacokinetics and Pharmacodynamics of Once-Daily Growth Hormone Norditropin(®) in Children and Adults
por: Papathanasiou, Theodoros, et al.
Publicado: (2021) -
User assessment of Norditropin NordiFlex(®), a new prefilled growth hormone pen: a Phase IV multicenter prospective study
por: Tauber, Maithé, et al.
Publicado: (2013) -
User assessment of Norditropin NordiFlex®, a new prefilled growth hormone pen: a Phase IV multicenter prospective study [Corrigendum]
Publicado: (2013) -
Effect of 4 years of growth hormone therapy in children with Noonan syndrome in the American Norditropin Studies: Web-Enabled Research (ANSWER) Program® registry
por: Lee, Peter A, et al.
Publicado: (2012) -
Growth hormone deficiency, acromegaly and COVID-19: Transitioning from media reports to knowledge and a growth hormone hypothesis
por: Yuen, Kevin C.J.
Publicado: (2021)